Significant reduction in chronic kidney disease progression with sodium glucose co-transporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in UK clinical setting: An observational outcomes study based on international guidelines for kidney disease

AIMS: This observational study aims to confirm the reno-protective effects of sodium-glucose co-transporter-2 inhibitors (SGLT2i) compared with dipeptidyl peptidase-4 inhibitors (DPP4i) on the onset and progression of chronic kidney disease (CKD) in a routine clinical practice. MATERIALS AND METHODS: This was a retrospective cohort study using the Clinical Practice Research Datalink Aurum database linked to Hospital Episode Statistics. The primary outcome was risk of the composite CKD endpoints based on the recent consensus guidelines for kidney disease: >40% decline in estimated glomerular filtration rate, kidney death or end-stage kidney disease (ESKD; a composite of kidney transplantation, maintenance of dialysis, sustained low eGFR